Understanding and treating neurogenetic conditions related to the Kennedy pathway

了解和治疗与肯尼迪通路相关的神经遗传疾病

基本信息

  • 批准号:
    MR/Y014251/1
  • 负责人:
  • 金额:
    $ 88.32万
  • 依托单位:
  • 依托单位国家:
    英国
  • 项目类别:
    Research Grant
  • 财政年份:
    2024
  • 资助国家:
    英国
  • 起止时间:
    2024 至 无数据
  • 项目状态:
    未结题

项目摘要

The hereditary spastic paraplegias (HSP)s are a large group of debilitating genetic disorders that lead to lower limb weakness and stiffness (spasticity). Unfortunately, the condition progresses, leading to patients experiencing increasing difficulties. In some forms of HSP, symptoms are confined to the lower limbs, while other patients may suffer a wider range of medical problems (referred to as complex HSP). In this proposal we will investigate two complex forms of HSP, known as SPG81 and SPG82. These complex HSPs are caused by mutations in genes that encode enzymes of the so-called Kennedy pathway of lipid metabolism. This pathway makes two types of phospholipids, which are essential fat-like molecules that help generate cell membranes (barriers that enclose the cell from the surrounding environment and also make internal compartments inside the cell). We will also study a third disease that affects the nervous system, with similar clinical features to SPG81 and SPG82, called NEDMIMS, which is caused by mutations in another gene encoding an enzyme in the Kennedy pathway.Currently, we lack understanding of the pathological mechanisms of NEDMIMS and SPG81 and 82, and there are no effective treatments. In this proposal, we will use zebrafish to model the three genetic conditions (SPG81, SPG82 and NEDMIMS) to reveal disease mechanisms and test new potential therapeutic strategies. Our preliminary work indicates that SPG82 can be modelled faithfully in zebrafish, with reduced head size and defective movement, and changes in lipids similar to those seen in patients. Our initial experiments will perform the analysis of the physical features of the SPG81 and NEDMIMS zebrafish models, which will be combined with measurements of lipid types and abundance. In subsequent experiments we will carry out a detailed analysis of the nervous system in all 3 models using a variety of advanced approaches, which includes microscopy and an extensive analysis of the cell types, cellular components, and molecular pathways that are affected. This will allow us to obtain a detailed molecular description of the processes that occur in the disease state, and hence identify the pathological mechanisms involved. In the final part of the project we will try various approaches to rescue the disease pathology. This will include genetic approaches where we re-express a 'normal' copy of the affected gene, and chemical ones, where we will treat the zebrafish with selected drugs or a larger library of drugs. Those treatments that rescue the pathology may then be exploited in further testing that would follow on from this award. Importantly, the HSPs are progressive in nature and hence there is a therapeutic window, making treatment of patients possible. This work is important because it will identify the mechanisms of three highly debilitating genetic conditions, and allow the identification of new potential treatments for them. It will also have relevance for other similar types of neurological conditions, including the HSPs more generally, as well other types of motor neurone disease.
遗传性痉挛性截瘫 (HSP) 是一大类使人衰弱的遗传性疾病,会导致下肢无力和僵硬(痉挛)。不幸的是,病情不断发展,导致患者遇到越来越多的困难。在某些形式的 HSP 中,症状仅限于下肢,而其他患者可能会遭受更广泛的医疗问题(称为复杂 HSP)。在本提案中,我们将研究两种复杂形式的 HSP,即 SPG81 和 SPG82。这些复杂的热休克蛋白是由编码所谓肯尼迪脂质代谢途径的酶的基因突变引起的。该途径产生两种类型的磷脂,它们是必需的类脂肪分子,有助于生成细胞膜(将细胞与周围环境隔离开的屏障,并在细胞内部形成内部隔室)。我们还将研究第三种影响神经系统的疾病,其临床特征与 SPG81 和 SPG82 类似,称为 NEDMIMS,它是由编码 Kennedy 通路中一种酶的另一个基因突变引起的。目前,我们对其病理机制缺乏了解。 NEDMIMS 和 SPG81 和 82,并且没有有效的治疗方法。在本提案中,我们将使用斑马鱼对三种遗传条件(SPG81、SPG82 和 NEDMIMS)进行建模,以揭示疾病机制并测试新的潜在治疗策略。我们的初步工作表明,SPG82 可以在斑马鱼中忠实地建模,其头部尺寸减小,运动缺陷,并且脂质变化与在患者中看到的相似。我们的初步实验将对 SPG81 和 NEDMIMS 斑马鱼模型的物理特征进行分析,并将其与脂质类型和丰度的测量相结合。在后续实验中,我们将使用各种先进方法对所有 3 个模型中的神经系统进行详细分析,其中包括显微镜以及对受影响的细胞类型、细胞成分和分子途径的广泛分析。这将使我们能够获得疾病状态下发生的过程的详细分子描述,从而确定所涉及的病理机制。在该项目的最后部分,我们将尝试各种方法来挽救疾病病理。这将包括遗传方法,我们重新表达受影响基因的“正常”副本,以及化学方法,我们将用选定的药物或更大的药物库治疗斑马鱼。这些挽救病理的治疗方法可能会被用于该奖项之后的进一步测试。重要的是,热休克蛋白本质上是渐进的,因此存在治疗窗口,使患者的治疗成为可能。这项工作很重要,因为它将确定三种高度衰弱的遗传性疾病的机制,并为它们找到新的潜在治疗方法。它还与其他类似类型的神经系统疾病相关,包括更普遍的热休克蛋白,以及其他类型的运动神经元疾病。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Martin Lowe其他文献

Glutamate Release from Guinea‐Pig Synaptosomes: Stimulation by Reuptake‐Induced Depolarization
豚鼠突触体中谷氨酸的释放:再摄取诱导的去极化的刺激
  • DOI:
    10.1111/j.1471-4159.1989.tb07296.x
  • 发表时间:
    1989
  • 期刊:
  • 影响因子:
    4.7
  • 作者:
    H. McMahon;A. Barrie;Martin Lowe;D. Nicholls
  • 通讯作者:
    D. Nicholls
Response to Letter Regarding Article, “High-Density Substrate Mapping in Brugada Syndrome: Combined Role of Conduction and Repolarization Heterogeneities in Arrhythmogenesis”
对有关文章“布鲁格达综合征的高密度基质测绘:传导和复极异质性在心律失常发生中的综合作用”的信件的回复
  • DOI:
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    0
  • 作者:
    PD Lambiase;A. Ahmed;R. Ben;A. Chow;Martin Lowe;William J. McKenna;Edward J. Ciaccio;Ramon Brugada;É. Lizotte;Chaubey
  • 通讯作者:
    Chaubey
High prevalence of early repolarization in the pediatric relatives of Sudden Arrhythmic Death Syndrome (SADS) victims and in normal controls
心律失常性死亡综合症 (SADS) 患者的儿科亲属和正常对照中早期复极的发生率较高
  • DOI:
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    0
  • 作者:
    A. McCorquodale;R. Poulton;J. Hendry;G. Norrish;E. Field;Sarah;Mead;Martin Lowe;J. Kaski
  • 通讯作者:
    J. Kaski
Membrane transport: Tethers and TRAPPs
膜运输:系链和 TRAPP
  • DOI:
    10.1016/s0960-9822(00)00505-4
  • 发表时间:
    2000
  • 期刊:
  • 影响因子:
    9.2
  • 作者:
    Martin Lowe
  • 通讯作者:
    Martin Lowe
Novel repolarisation metric predicts arrhythmia origin and clinical events in ARVC and Brugada Syndrome
新型复极指标可预测 ARVC 和 Brugada 综合征的心律失常起源和临床事件
  • DOI:
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    0
  • 作者:
    C. Martin;M. Orini;N. Srinivasan;J. Bhar;S. Honarbakhsh;A. Chow;Martin Lowe;Ron D.B. Simon;Perry M. Elliott;P. Taggart;P. Lambiase
  • 通讯作者:
    P. Lambiase

Martin Lowe的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Martin Lowe', 18)}}的其他基金

Determining the specificity of vesicle traffic at the Golgi apparatus
确定高尔基体囊泡运输的特异性
  • 批准号:
    BB/X006859/1
  • 财政年份:
    2023
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
Coordination of membrane traffic in the early secretory pathway
早期分泌途径中膜运输的协调
  • 批准号:
    BB/S014799/1
  • 财政年份:
    2019
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
A new role for intermediate filaments in the secretory pathway
中间丝在分泌途径中的新作用
  • 批准号:
    BB/T000945/1
  • 财政年份:
    2019
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
Mechanisms of endocytic recycling in the renal proximal tubule
肾近曲小管内吞再循环机制
  • 批准号:
    BB/N000641/1
  • 财政年份:
    2016
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
Dissecting the function of GORAB, the protein mutated in Geroderma osteodysplastica
剖析 GORAB 的功能,GORAB 是骨发育不良中突变的蛋白质
  • 批准号:
    MR/N000366/1
  • 财政年份:
    2015
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
The role of OCRL1 in endocytic membrane traffic
OCRL1在内吞膜运输中的作用
  • 批准号:
    MR/K000810/1
  • 财政年份:
    2013
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
Dissecting the roles of ZFPL1 and GMAP210 in Golgi biogenesis and membrane traffic
剖析 ZFPL1 和 GMAP210 在高尔基体生物发生和膜运输中的作用
  • 批准号:
    BB/I007717/1
  • 财政年份:
    2011
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
A Manchester-Beijing Strategic Parntership in Molecular Life Sciences
曼彻斯特-北京分子生命科学战略合作伙伴关系
  • 批准号:
    BB/H531600/1
  • 财政年份:
    2010
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
Mitotic regulation of the Golgi apparatus- the role of the ARF nucleotide exchange factor GBF1
高尔基体的有丝分裂调节——ARF核苷酸交换因子GBF1的作用
  • 批准号:
    BB/F005628/1
  • 财政年份:
    2008
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
Molecular organisation of the secretory and endocytic pathways
分泌和内吞途径的分子组织
  • 批准号:
    G0501725/1
  • 财政年份:
    2006
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant

相似国自然基金

AUTS2通过表观遗传调控BRN2转录活性影响肿瘤微环境促进治疗相关神经内分泌前列腺癌发生的研究
  • 批准号:
    82303905
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
基于神经影像和多组学解析早期帕金森病抑郁发生和药物治疗的双环路机制
  • 批准号:
    82371268
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
基于A20去泛素化修饰STAT6改善成年海马神经发生探讨菟丝子治疗老年抑郁症的分子机制
  • 批准号:
    82160860
  • 批准年份:
    2021
  • 资助金额:
    34 万元
  • 项目类别:
    地区科学基金项目
青蒿琥酯调控神经发生治疗脆性X染色体综合征认知功能障碍的分子机制研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目

相似海外基金

AMPQuest - Journeying to new horizons in treating drug-resistant infections.
AMPQuest - 迈向治疗耐药感染的新视野。
  • 批准号:
    BB/Y514019/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
ICF - Evaluate the potential of AstraZeneca's sialic acid tag technology for treating influenza viruses with Fc molecules
ICF - 评估阿斯利康唾液酸标签技术用 Fc 分子治疗流感病毒的潜力
  • 批准号:
    MR/Y503459/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
Amyotrophic Lateral Sclerosis: treating the circuit behind the disease
肌萎缩侧索硬化症:治疗疾病背后的回路
  • 批准号:
    MR/Y014901/1
  • 财政年份:
    2024
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Research Grant
A Novel Ruthenium Antimicrobial Platform Technology - Preventing and Treating Multi-Drug Resistant Infections
新型钌抗菌平台技术——预防和治疗多重耐药感染
  • 批准号:
    10050214
  • 财政年份:
    2023
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Grant for R&D
Targeting Ryanodine Receptor 2 for Treating Neonatal Hypoxic-ischemic Brain Injury (HIBI)
靶向 Ryanodine 受体 2 治疗新生儿缺氧缺血性脑损伤 (HIBI)
  • 批准号:
    488816
  • 财政年份:
    2023
  • 资助金额:
    $ 88.32万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了